Paper - WANFANG MED ONLINE

You Position: Home > Paper

Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management

( views:393, downloads:308 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 1

DOI:: 10.3760/cma.j.issn.1674-2397.2013.01.001

Key Word:: 肝炎,乙型,慢性;抗药性;核苷和核苷酸类药物;管理;Hepatitis B,chronic;Drug resistance;Nucleoside and nucleotide analogs;Management

Abstract：在核苷和核苷酸类药物(nucleoside and nucleotide analogs,NAs)治疗慢性乙型肝炎过程中,耐药是一个极为重要的问题.与未发生耐药的患者比较,耐药不仅可导致疾病进一步进展,并可增加发生肝功能失代偿和肝细胞癌(HCC)的风险;还会加大后续治疗的难度,增加长期治疗的医疗成本.因此,耐药的预防和管理是提高疗效、缩短疗程、改善预后和减少医疗成本的重要措施.近年来,我国、亚太、欧洲和美国肝病学会先后对慢性乙型肝炎诊治指南或共识进行了更新,对NAs耐药的预防和管理提出了新的认识和建议[1-4].2008年我国有关专家曾发表《乙型肝炎病毒耐药专家共识》(以下简称《共识》)[5],并在2009年更新[6].

Reference

[1]董南,何波,庄辉.慢性乙型肝炎患者对疾病和抗病毒治疗的认知程度调查[J].2009,(1).
[2]乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识[J].2008,(1).
[3]乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识：2009年更新[J].2009,(1).
[4]Lok AS,McMahon BJ.Chronic hepatitis B: update 2009.[J].2009,50(3).
[5]Pawlotsky JM,Richman DD,Lau G,etc.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.[J].2008,134(2).
[6]Yuen L,Locarnini SA.Molecular genesis of drug-resistant and vaccine-escape HBV mutants.[J].2010,15(3 Pt.B).
[7]Zeuzem S,Gane E,Liaw YF.Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.[J].2009,51(1).
[8]Zoulim,F.,Jia,J.-D.,Locarnini,S.,etc.Selection of chronic hepatitis B therapy with high barrier to resistance[J].2012,12(4).
[9]Chen L,Yu JL,Gong QM,etc.Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy.[J].2011,60(9).
[10]Chau-Ting Yeh,Tiffany Chen,Chao-Wei Hsu,etc.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B[J].2011,11(1).
[11]Omata M,Yokosuka O,Masaki N,etc.Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection.[J].2010,52(6).
[12]Sozzi V,Campbell K,Walker CM,etc.Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.[J].2009,49(5).
[13]Henry Lik Yuen Chan,Jia-Horne Kao,Teerha Piratvisuth,etc.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J].2012,6(3).
[14]Sheldon J,Locarnini S,Camino N,etc.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.[J].2005,10(6).
[15]Zoulim F.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection.[J].2004,64(1).
[16]Stephen Locarnini,Fabien Zoulim.Management of treatment failure in chronic hepatitis B.[J].2012,56(Suppl.1).
[17]Maimuna M,Dusheiko G,Wiersma ST,etc.Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus.[J].2011,31(6).
[18]孙秘书,王贵强,张伟,等.拉米夫定经治慢性乙型肝炎患者治疗现状调查分析[J].2012,(1).
[19]Heathcote J,Myrick F,Borroto Esoda K,etc.No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.[J].2011,53(3).
[20]Y. Liu,C. Wang,Y. Zhong,etc.Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection[J].2011,18(4).
[21]Xu Z,Liu Y,Xu T,etc.Acute hepatitis B infection associated with drug-resistant hepatitis B virus.[J].2010,48(4).
[22]Ollivet A,Barraud L,Villeneuve JP,etc.Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.[J].2007,46(3).
[23][Noauthornameavailable].EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J].2012,57(1).
[24]Cursaro C,Fung S,Sablon E,etc.Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.[J].2006,44(3).
[25]Earnest Silveira L,Deliyannis G,Sozzi T,etc.Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.[J].2002,293(2).
[26]Borroto-Esoda K,Sievert W,Tong M,etc.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.[J].2008,48(3).
[27]Zhang XX,Zhang Q,Yu DM,etc.Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy.[J].2009,50(5).
[28]van Bommel F,de Man RA,Wedemeyer.Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.[J].2010,51(1).
[29]Zhang JM,Li XH,Wang YM,etc.Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.[J].2011,34(4).
[30]Janssen HL.Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virological response.[J].2011,54(2).
[31]Locarnini S.Molecular virology of hepatitis B virus.[J].2004,24(Suppl.1).
[32]Terrault NA.Benefits and risks of combination therapy for hepatitis B.[J].2009,49(5 Suppl.).
[33]Decraemer H,Hulstaert F,Lok AS,etc.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.[J].2002,40(10).
[34]Pawlotsky JM,Dieterich DT,Benhamou Y,etc.Chronic hepatitis B: preventing, detecting, and managing viral resistance.[J].2008,6(3).
[35]Wedemeyer H,Reijnders JG,Buti M,etc.Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.[J].2010,52(4).
[36]Chung HJ,Kim SO,Ahn SH,etc.Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization.[J].2005,10(3).
[37]Licari,T.,Fontana,R.J.,Oberhelman,K.,etc.Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs[J].2012,19(3).
[38]De Gendt-S,Rossau R,Van Reybroeck-G,etc.Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.[J].2000,38(2).
[39]Roberts SK,Sievert W,Nicoll AJ,etc.Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.[J].2011,60(2).
[40]Hongthanakorn C,Oberhelman K,Lok AS,etc.Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.[J].2011,53(6).
[41]Levine SM,Bartholomeusz A,Pokornowski K,etc.Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.[J].2004,48(9).
[42]Warner N,Locarnini S.The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.[J].2008,48(1).
[43]Esteban R,Woessner MA,Heathcote EJ,etc.Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.[J].2005,42(2).
[44]Schiff ER,Jacobson IM,Keeffe EB,etc.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.[J].2008,6(12).
[45]Cui ZY,Yao JL,Zhu M,etc.A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.[J].2009,10(2).
[46]Bourne EJ,Baldanti F,Ross LL,etc.Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine.[J].1999,37(10).